CORE--Molecular Resources Core

CORE--分子资源核心

基本信息

  • 批准号:
    7312504
  • 负责人:
  • 金额:
    $ 27.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-03-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

Core C, the Molecular Resources Core, will provide molecular reagents and services to all four projects and will be crucial to the completion of the specific aims of each proposal in the Program Project. The proposal for a Molecular Resources Core is a continuation of the original Core C. The overall function of Core C is to provide molecular reagents and expertise, including generation of deletion and site-directed mutants and incorporation into the desired expression vectors, creation of minigene constructs, generation of adenoviral and retroviral constructs for transduction of primary endothelial cells and designing and generating appropriate siRNA based constructs. This core will be directed by Dr. Randal A. Skidgel and will be staffed by a full-time Senior Research Specialist (Dr. Barbara Keith), full- time Research Specialist (TBN) and part-time Research Associate (Vidas Dumasias). Consolidating these efforts in Core C will result in increased speed and efficiency in accomplishing the research tasks outlined in each of the projects and uniformity of approaches and methods so that resutts from each project can be compared. In addition, it will allow strict quality control and consistency of molecular reagents to be used by the various projects. Furthermore, an added and important benefit of the centralized Core C will be to markedly decrease expenses compared to a scenario in which each project would generate its own molecular resources. Regular meetings of the Core leader with the Senior Research Specialist and project leaders will assure coordination and prioritization of the generation of molecular reagents and assure that the desired reagents are provided in a timely manner to the component projects.
核心C,即分子资源核心,将为所有四个项目提供分子试剂和服务,并将对完成计划项目中每个提案的具体目标至关重要。Core的总体功能是提供分子试剂和专业知识,包括产生缺失和定点突变体,并将其整合到所需的表达载体中,创建minigene构建体,生成用于原代内皮细胞转导的腺病毒和逆转录病毒构建体,以及设计和生成适当的基于siRNA的构建体。该核心将由Randal a . Skidgel博士指导,并将由全职高级研究专家(Barbara Keith博士),全职研究专家(TBN)和兼职研究助理(Vidas Dumasias)组成。将这些努力整合到核心C中,将提高完成每一份报告中概述的研究任务的速度和效率

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Randal A Skidgel其他文献

Randal A Skidgel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Randal A Skidgel', 18)}}的其他基金

Developing a new drug for treating myocardial ischemia/reperfusion injury
开发治疗心肌缺血/再灌注损伤的新药
  • 批准号:
    10491205
  • 财政年份:
    2021
  • 资助金额:
    $ 27.47万
  • 项目类别:
Developing a new drug for treating myocardial ischemia/reperfusion injury
开发治疗心肌缺血/再灌注损伤的新药
  • 批准号:
    10325868
  • 财政年份:
    2021
  • 资助金额:
    $ 27.47万
  • 项目类别:
Targeting integrin outside-in signaling for treating sepsis
靶向整合素由外向内信号传导治疗脓毒症
  • 批准号:
    10461718
  • 财政年份:
    2018
  • 资助金额:
    $ 27.47万
  • 项目类别:
Targeting integrin outside-in signaling for treating sepsis
靶向整合素由外向内信号传导治疗脓毒症
  • 批准号:
    10625353
  • 财政年份:
    2018
  • 资助金额:
    $ 27.47万
  • 项目类别:
Post-translational Regulation of High Output NO and Endothelial Barrier Dysfuncti
高输出 NO 和内皮屏障功能障碍的翻译后调节
  • 批准号:
    8059128
  • 财政年份:
    2011
  • 资助金额:
    $ 27.47万
  • 项目类别:
Molecular Resources Core
分子资源核心
  • 批准号:
    8059136
  • 财政年份:
    2011
  • 资助金额:
    $ 27.47万
  • 项目类别:
CORE--Molecular Resources Core
CORE--分子资源核心
  • 批准号:
    7367825
  • 财政年份:
    2007
  • 资助金额:
    $ 27.47万
  • 项目类别:
Post-Translational Regulation of High Output NO and Endothelial Barrier Dysfuncti
高输出 NO 和内皮屏障功能障碍的翻译后调节
  • 批准号:
    7367821
  • 财政年份:
    2007
  • 资助金额:
    $ 27.47万
  • 项目类别:
Post-Translational Regulation of High Output NO and Endothelial Barrier Dysfuncti
高输出 NO 和内皮屏障功能障碍的翻译后调节
  • 批准号:
    7312500
  • 财政年份:
    2006
  • 资助金额:
    $ 27.47万
  • 项目类别:
Post-Translational Regulation of High Output NO and Endothelial Barrier Dysfuncti
高输出 NO 和内皮屏障功能障碍的翻译后调节
  • 批准号:
    6967980
  • 财政年份:
    2005
  • 资助金额:
    $ 27.47万
  • 项目类别:

相似海外基金

BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    4691285
  • 财政年份:
  • 资助金额:
    $ 27.47万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    3815902
  • 财政年份:
  • 资助金额:
    $ 27.47万
  • 项目类别:
BIOMEDICAL FACILITY EQUIPMENT
生物医学设施设备
  • 批准号:
    3931637
  • 财政年份:
  • 资助金额:
    $ 27.47万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    3819816
  • 财政年份:
  • 资助金额:
    $ 27.47万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    3961763
  • 财政年份:
  • 资助金额:
    $ 27.47万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    3811789
  • 财政年份:
  • 资助金额:
    $ 27.47万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    3937887
  • 财政年份:
  • 资助金额:
    $ 27.47万
  • 项目类别:
BIOMEDICAL FACILITY
生物医学设施
  • 批准号:
    4690608
  • 财政年份:
  • 资助金额:
    $ 27.47万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了